Detalles de la búsqueda
1.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Ann Oncol
; 33(6): 593-601, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219776
2.
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.
BMC Cancer
; 22(1): 276, 2022 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35291965
3.
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Ann Oncol
; 31(2): 236-245, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31959340
4.
Exaggeration of PFS by blinded, independent, central review (BICR).
Ann Oncol
; 30(2): 332-338, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30475951
5.
Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.
Breast Cancer Res Treat
; 176(2): 357-365, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31028610
6.
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Ann Oncol
; 28(8): 1842-1848, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28481967
7.
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
Ann Oncol
; 28(8): 1849-1855, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28595285
8.
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Ann Oncol
; 27(8): 1505-10, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27407100
9.
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Ann Oncol
; 27(9): 1733-9, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27287207
10.
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Ann Oncol
; 27(5): 806-12, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26861603
11.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Br J Cancer
; 112(6): 963-70, 2015 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25742472
12.
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
Int J Obes (Lond)
; 39(5): 849-57, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25520249
13.
Meta-analysis of radical resection rates and margin assessment in pancreatic cancer.
Br J Surg
; 102(12): 1459-72, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26350029
14.
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Ann Oncol
; 25(1): 117-21, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24299960
15.
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Ann Oncol
; 25(1): 143-8, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356625
16.
Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
Int J Obes (Lond)
; 38(9): 1165-71, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24406481
17.
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer.
Br J Cancer
; 109(1): 147-53, 2013 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23778526
18.
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.
Br J Cancer
; 108(4): 771-4, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23412099
19.
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Ann Oncol
; 24(4): 937-43, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23104722
20.
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.
Support Care Cancer
; 21(6): 1561-8, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23274926